TY - JOUR
T1 - 15-year experience with rotavirus vaccination in Mexico
T2 - a systematic literature review
AU - Guzman-Holst, Adriana
AU - Ortega-Barria, Eduardo
AU - Flores, Ángel Alexis
AU - Carreño-Manjarrez, Roberto
AU - Constenla, Dagna
AU - Cervantes-Apolinar, Maria Yolanda
N1 - Funding Information:
GlaxoSmithKline Biologicals SA funded this study [HO-19-20101] and took in charge all costs associated with the development and publication of this manuscript. The authors would also like to thank the Business & Decision Life Sciences platform for editorial assistance and manuscript coordination, on behalf of GSK. Maxime Bessières coordinated manuscript development and editorial support and Amrita Ostawal (Arete Communication UG) provided writing support for this literature review.
Publisher Copyright:
© 2021 GlaxoSmithKline Biologicals S.A. Published with license by Taylor & Francis Group, LLC.
PY - 2021
Y1 - 2021
N2 - A systematic review was conducted in Mexico to consolidate and evaluate evidence after 15 years of rotavirus vaccination, according to the National Immunization Program. Five databases were screened to identify published articles (January 2000–February 2020) with evidence on all clinical and epidemiological endpoints (e.g. immunogenicity, safety, efficacy, impact/effectiveness) of rotavirus vaccination in Mexico. Twenty-two articles were identified (observational studies including health-economic models: 17; randomized controlled trials: 5). Fourteen studies evaluated a human attenuated vaccine (HRV), four studies evaluated both vaccines, and only two evaluated a bovine-human reassortant vaccine, with local efficacy data only for HRV. Local evidence shows vaccines are safe, immunogenic, efficacious, and provide an acceptable risk-benefit profile. The benefits of both vaccines in alleviating the burden of all-cause diarrhea mortality and morbidity are documented in several local post-licensure studies. Findings signify overall benefits of rotavirus vaccination and support the continued use of rotavirus vaccine in Mexico.
AB - A systematic review was conducted in Mexico to consolidate and evaluate evidence after 15 years of rotavirus vaccination, according to the National Immunization Program. Five databases were screened to identify published articles (January 2000–February 2020) with evidence on all clinical and epidemiological endpoints (e.g. immunogenicity, safety, efficacy, impact/effectiveness) of rotavirus vaccination in Mexico. Twenty-two articles were identified (observational studies including health-economic models: 17; randomized controlled trials: 5). Fourteen studies evaluated a human attenuated vaccine (HRV), four studies evaluated both vaccines, and only two evaluated a bovine-human reassortant vaccine, with local efficacy data only for HRV. Local evidence shows vaccines are safe, immunogenic, efficacious, and provide an acceptable risk-benefit profile. The benefits of both vaccines in alleviating the burden of all-cause diarrhea mortality and morbidity are documented in several local post-licensure studies. Findings signify overall benefits of rotavirus vaccination and support the continued use of rotavirus vaccine in Mexico.
KW - Mexico
KW - acute diarrhea
KW - disease burden
KW - health economics
KW - immunogenicity
KW - intussusception
KW - rotavirus gastroenteritis
KW - rotavirus vaccine
KW - systematic review
UR - http://www.scopus.com/inward/record.url?scp=85109023037&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109023037&partnerID=8YFLogxK
U2 - 10.1080/21645515.2021.1936859
DO - 10.1080/21645515.2021.1936859
M3 - Review article
C2 - 34187326
AN - SCOPUS:85109023037
SN - 2164-5515
VL - 17
SP - 3623
EP - 3637
JO - Human Vaccines and Immunotherapeutics
JF - Human Vaccines and Immunotherapeutics
IS - 10
ER -